Identification of a novel MCR-1 variant displaying low level of co-resistance to β-lactam antibiotics that uncovers a potential novel antimicrobial peptide

Lujie Liang,Lan-Lan Zhong,Lin Wang,Dianrong Zhou,Yaxin Li,Jiachen Li,Yong Chen,Wanfei Liang,Wenjing Wei,Chenchen Zhang,Hui Zhao,Lingxuan Lyu,Nicole Stoesser,Yohei Doi,David L Paterson,Fang Bai,Siyuan Feng,Guo-Bao Tian

DOI: https://doi.org/10.1101/2023.04.03.535341

2023-01-01

Abstract:The emerging and global spread of a novel plasmid-mediated colistin resistance gene, mcr-1 , threatens human health. It is accepted that MCR-1 affects bacterial fitness, and this fitness cost correlates with bacterial membrane lipid A perturbation. However, the detailed molecular mechanism remains unclear. Here, we screened out a novel MCR-1 variant, named M6, with a two-point mutation that rendered a low level of co-resistance to β-lactam antibiotics. Compared to wild-type (WT) MCR-1, this variant caused severe lipid A perturbation resulting in peptidoglycan layer remodelling and thus resulted in phenotypic co-resistance to β-lactams. Moreover, we found that a lipid A loading cavity is localized at the linker domain of MCR-1 and governs colistin resistance and bacterial membrane permeability, and the mutated pocket of M6 facilitates the binding affinity of lipid A. More importantly, synthetic peptides derived from M6 achieved broad-spectrum antimicrobial activity. These findings provide insights into a potential vulnerability that could be exploited in future antimicrobial drug design. ### Competing Interest Statement The authors have declared no competing interest.